Hydroxychloroquine Ineffective for Hand Osteoarthritis Pain Management

Study Findings

A recent study published in the medical journal Trials indicates that hydroxychloroquine does not provide any significant benefits over a placebo in managing pain associated with osteoarthritis. The editors of the BMJ emphasize in a news article that prescribing this medication is not warranted due to its lack of efficacy.

Understanding Hand Osteoarthritis

Researchers in England explored the effectiveness of hydroxychloroquine in alleviating pain specifically related to hand osteoarthritis. This condition is characterized by joint inflammation in the hand, leading to debilitating pain and functional loss. The symptoms significantly reduce the quality of life, making routine tasks such as writing, cooking, and gripping objects increasingly challenging.

Treatment Options

Current treatment strategies for hand osteoarthritis primarily focus on pain management through medications like acetaminophen, ibuprofen, and capsaicin cream. Hydroxychloroquine, often prescribed for rheumatoid arthritis, lacks sufficient evidence supporting its use in treating hand osteoarthritis.

Details of the Study

A research article in the British Medical Journal reviewed a study led by Sarah Kingsbury and her team in the UK. The study aimed to assess the effectiveness of hydroxychloroquine in managing pain related to hand osteoarthritis. A total of 248 participants were recruited from thirteen primary and secondary care centers across England. They were randomly assigned to receive either hydroxychloroquine (200mg-400mg) or a placebo. Key outcomes measured included hand pain, grip strength, function, and overall quality of life.

Results of the Research

After six months, the researchers found no significant difference in hand pain between the hydroxychloroquine group and the placebo group. Additionally, there was no notable difference in grip strength, functional capacity, or quality of life. The study noted a limitation regarding the dosing of hydroxychloroquine, which was lower than the standard starting dose recommended for initiating rheumatoid arthritis therapy. Participants received a maximum of 6.5mg/kg per day, with most patients on a daily dose of 300mg.

Conclusion

The findings from this study do not support the use of hydroxychloroquine for treating pain associated with hand osteoarthritis. The noted limitations could have influenced these results. Further research into treatment options for hand osteoarthritis is essential to enhance the quality of life for affected patients.

References

(1) Wise, J. Hydroxychloroquine should not be used for hand osteoarthritis, say researchers. BMJ 2018;360:k774 doi: 10.1136/bmj.k774
(2) Kingsbury SR, Tharmanathan P, Adamson J, et al. Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis (HERO): study protocol for a randomized controlled trial. Trials. 2013;14:64. doi:10.1186/1745-6215-14-64.